Sentinel API Group is bringing essential drug ingredients back to the US: GMP-first, repeatable “production trains,” built to scale fast and stop shortages.
Sentinel API Group is reshoring US domestic active pharmaceutical manufacturing platform focused on essential high-volume generic medicines. No R&D, No clinical trial tail, and DMF ready day one. Policy-backed, Grant leveraged, and capital staged for scale. The plan is built, the people are in place, and the mission is urgent.
This section is only visible to registered investors. Log in or register as an accredited investor to view.
Ready to Ask For Funding for your company?
Post a Funding Request